Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR‐Altered Bladder Cancer
Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR‐Altered Bladder Cancer
About this item
Full title
Author / Creator
Publisher
Germany: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Germany: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Fibroblast growth factor receptor (FGFR) family aberrations are common in urothelial cancer. The FGFR tyrosine kinase inhibitor erdafitinib has been approved for locally advanced or metastatic urothelial cancer with FGFR2/3 alterations. Despite the initial efficacy of erdafitinib, resistance cannot be avoided. The molecular mechanisms underlying er...
Alternative Titles
Full title
Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR‐Altered Bladder Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_977ad6c518a14b2fa67b012444fa2371
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_977ad6c518a14b2fa67b012444fa2371
Other Identifiers
ISSN
2198-3844
E-ISSN
2198-3844
DOI
10.1002/advs.202413209
